Rheumatoid Arthritis News and Research RSS Feed - Rheumatoid Arthritis News and Research

Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.

RA is an autoimmune disease, meaning the immune system, which is usually geared up to fight infection, attacks the lining of the joints, causing them to swell and become stiff and painful. Eventually, the joint itself can become damaged as well as the cartilage and surrounding bone. Any joint can be affected but most commonly the illness involves the hands, feet and wrists.

The condition is more common among women than men and usually affects people between the ages of 40 and 70, although it can affect people of any age.

Symptoms range from mild to severe and can flare-up suddenly and unpredictably, making the condition very difficult to live with.

The exact cause of rheumatoid arthritis is not yet fully understood but some research suggests that viruses and bacteria may be involved. RA cannot be cured but early diagnosis and treatment can help to manage symptoms and prevent disability.
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
AMGF participates in collaborative effort to find best practices in managing RA patients

AMGF participates in collaborative effort to find best practices in managing RA patients

The American Medical Group Foundation today announced participants in a collaborative dedicated to finding best practices in managing patients with rheumatoid arthritis (RA). [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
Research shows new drug candidate can stop tumor growth in animal models

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable." [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Rheumatoid arthritis is a condition that causes painful inflammation of several joints in the body. The joint capsule becomes swollen, and the disease can also destroy cartilage and bone as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world's population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease. [More]
Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients. [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

There is no cure for Alzheimer's disease and other forms of dementia, but the research community is one step closer to finding treatment. [More]
XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown. [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases. [More]
Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue is about much more than merely feeling tired and when it is at its worst, people feel unable to do almost anything, so it can impact absolutely every area of their life. [More]
Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark Pharmaceuticals Ltd, a research-driven, global, integrated pharmaceutical company, plans to set up a new manufacturing facility in the US. [More]
Novagant releases GoldenCBD oil including capsules and liquids

Novagant releases GoldenCBD oil including capsules and liquids

Novagant Corp. is pleased to announce that in this month of July it will release its GoldenCBD™ oil that will be available in several forms, including capsules and liquids. It will be the answer for those Medical Cannabis Patients living outside Washington and Colorado. [More]